<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04082741</url>
  </required_header>
  <id_info>
    <org_study_id>IM031-002</org_study_id>
    <nct_id>NCT04082741</nct_id>
  </id_info>
  <brief_title>A Single and Multiple Ascending Dose Study of BMS-986318 in Healthy Participants</brief_title>
  <official_title>A Phase 1, Double-Blind, Placebo-Controlled, Randomized Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Exploratory Pharmacodynamics of Oral BMS-986318 Administration in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate single and multiple ascending doses of experimental medicine BMS-986318
      in healthy participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1, Double-Blind, Placebo-Controlled, Randomized Single and Multiple Ascending Dose
      Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Exploratory
      Pharmacodynamics of Oral BMS-986318 Administration in Healthy Participants
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The study is no longer required based on nonclinical drug data
  </why_stopped>
  <start_date type="Actual">July 18, 2019</start_date>
  <completion_date type="Actual">September 12, 2019</completion_date>
  <primary_completion_date type="Actual">September 12, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of non-serious adverse events (AEs)</measure>
    <time_frame>up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAE)</measure>
    <time_frame>up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs leading to discontinuation of study treatment</measure>
    <time_frame>up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Examination of height</measure>
    <time_frame>up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Examination of weight</measure>
    <time_frame>up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Examination of BMI</measure>
    <time_frame>up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of body temperature</measure>
    <time_frame>up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of respiratory rate</measure>
    <time_frame>up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of blood pressure</measure>
    <time_frame>up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with 12-lead Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinical significant changes in lab assessment of blood serum</measure>
    <time_frame>up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Clinically significant changes in assessment of blood</measure>
    <time_frame>up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Clinically significant changes in lab assessment of urine</measure>
    <time_frame>up to 30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Monotherapy SAD BMS-986318 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Ascending Dose (SAD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy MAD BMS-986318 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple Ascending Dose (MAD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986318</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Monotherapy MAD BMS-986318 or Placebo</arm_group_label>
    <arm_group_label>Monotherapy SAD BMS-986318 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Matching BMS-986318</description>
    <arm_group_label>Monotherapy MAD BMS-986318 or Placebo</arm_group_label>
    <arm_group_label>Monotherapy SAD BMS-986318 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Participants as determined by no clinically significant deviations from normal
             in medical history, physical examination, ECG and clinical laboratory results as
             determined by the investigator

          -  Male participants who are sexually active with Women of Child Bearing Potential
             (WOCBP) must agree to follow instructions for methods of contraception for duration of
             treatment plus 92 days.

          -  Female participants must have documented proof that they are not of childbearing
             potential and a negative pregnancy test at screening and within 24 hours before the
             first dose of study treatment.

        Exclusion Criteria:

          -  Use of any prescription drugs within 4 weeks or use of over-the-counter (OTC)
             medications or herbal preparations within 2 weeks prior to study treatment
             administration (except acid controllers, which are not allowed within 4 weeks prior to
             study treatment administration

          -  Women of Child Bearing Potential (WOCBP) or women who are breastfeeding.

          -  Any major surgery within 12 weeks of study administration Or any history of GI
             surgeries as listed.(eg, gastric bypass, gastric banding, Roux-en-Y) or gastric-
             emptying issues that could impact upon the absorption of nutrients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences - Lenexa</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 15, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

